Ged Giblin
Corporate Officer/Principal presso Convergence Pharmaceuticals Ltd.
Posizioni attive di Ged Giblin
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | 06/10/2010 | - |
Storia della carriera di Ged Giblin
Precedenti posizioni note di Ged Giblin
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| GlaxoSmithKline (Pharmaceutical Operations) | Corporate Officer/Principal | - | - |
Statistiche
Distribuzione geografica
| Regno Unito | 2 |
| Stati Uniti | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
Settori
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| GlaxoSmithKline (Pharmaceutical Operations) |
- Borsa valori
- Insiders
- Ged Giblin
- Esperienza
